The added value of a platform approach: pen injector case study
Nemera is developing its pen injector platform and tailor to meet customer needs.
Radosław Romańczuk, MD, Pen Platform Business Development Director; Severine Duband, Category Director, Devices; and Audrey Chandra, Category Project Manager, all at Nemera, discuss the development of the company’s pen-injector platforms and how they are tailored to meet the customer’s needs.
The subcutaneous route of administration is highly preferable for many injectable drugs, such as trastuzumab, rituximab, bortezomib, granulocyte-colony stimulating factor (GCSF), immunoglobulins, epoetin alfa and heparin. For some drugs (e.g. insulin), the choice of administration route depends on the clinical circumstances.
In order to increase patients’ compliance and adherence, as well as to accommodate pharmaceuticals’ needs, developing a device platform needs to be strategically defined to ensure that it is designed for the maximum possible range of potential therapeutic areas and patient populations. This is to ultimately assure the device effectiveness.
Innovative technological solutions that offer a simple and intuitive user interface are easily adopted by patients. This favours adherence to therapy as well as safe and reliable dose delivery. Furthermore, successful technology can be applied to the development of other medical devices. By fostering the platform approach, coupled with Nemera’s integrated end-to-end service programme offerings, the company helps its customers accelerate their specific combination product development programmes in the sprint to market.
Nemera’s long-standing experience in the high-scale production of tailor-made pen injectors serves as a strong foundation and legacy that steers the company to go the extra mile, continuing its story.
Thanks in large part to the two strategic acquisitions made in the last couple of years, Nemera is well on its way to fulfilling its vision of becoming one of the most patient-centric drug delivery device companies worldwide.
To read the full article: Injectable Drug Delivery – April issue 120 – Nemera
To read the full magazine: Injectable Drug Delivery – April issue 120
As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit www.nemera.net